Zinc Acetate

Zinc acetate is elemental zinc bound to acetic acid — a water-soluble salt that is well absorbed and is the best-studied lozenge form in common-cold-duration trials. It is also the specific zinc salt approved for Wilson-disease maintenance (marketed as Galzin). For zinc’s full, form-agnostic evidence base — including the contested cold-lozenge data and complete intake references — see Zinc; this page covers what is specific to the acetate form.

Absorption & Tolerability

Zinc acetate is a water-soluble salt and sits with the well-absorbed group of zinc supplements. Head-to-head fractional-absorption work (using stable-isotope tracers) puts the soluble salts — gluconate and citrate — at roughly 61% absorption in adults taken without food, versus about 50% for the poorly soluble oxide, with a few individuals absorbing little or nothing from oxide ^{8Reference 8Wegmüller et al. · 2014RCTZinc absorption by young adults from supplemental zinc citrate is comparable with that from zinc gluconate and higher than from zinc oxide — randomized controlled trialView study →}. Acetate behaves as a soluble salt in that same group; there is no evidence it is a poor absorber, and the common “organic beats inorganic” marketing line is better read as “avoid oxide” than as any dramatic advantage of one soluble salt over another. As with all zinc, fractional absorption falls as the dose rises, so routine repletion is best split and taken with attention to food timing.

By weight, the dihydrate salt (Zn(CH₃COO)₂·2H₂O, the common commercial form) is ~30% elemental zinc; the anhydrous salt is ~36%. Always dose by elemental zinc, not by salt weight.

As a lozenge, acetate matters for a different reason: it is meant to dissolve slowly in the mouth and release ionic zinc locally in the pharynx, not to be swallowed. Zinc acetate releases zinc ions cleanly at mouth pH without the flavour-masking chelators (citric acid, sorbitol, mannitol) that can bind zinc and blunt the free-ion release in some gluconate formulations. The trade-off is a distinctive metallic taste and, at the high doses used in trials, frequent mouth and throat irritation and nausea. That strong taste is a recognised limitation of the trials themselves: it makes placebo blinding difficult and has been raised as a possible source of bias — although the pooled individual-patient analyses found the benefit held across subgroups and reported no serious adverse effects ^{4Reference 4Hemilä et al. · 2017Meta-analysisZinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis — meta-analysisView study →}.

What the Evidence Says

Two applications have data specific to the acetate salt. For everything else zinc is used for, see the Zinc hub.

Common-cold lozenges — where the acetate form earns its reputation

Zinc lozenges only shorten colds when the daily elemental-zinc dose is high (>75 mg/day) and the lozenge chemistry actually releases free zinc ions in the mouth — and zinc acetate is the form behind most of the strongly positive trials.

• A systematic review of 13 controlled comparisons found that five low-dose trials (<75 mg/day) uniformly showed no effect; three zinc-acetate trials at >75 mg/day pooled to a 42% reduction in cold duration (95% CI 35–48%), while five non-acetate salts at >75 mg/day gave a weaker 20% reduction (95% CI 12–28%) ^{1Reference 1Hemilä · 2011Systematic reviewZinc lozenges may shorten the duration of colds: a systematic review — systematic reviewView study →}.
• An individual-patient-data meta-analysis of three randomised, placebo-controlled acetate-lozenge trials (n = 199; 80–92 mg elemental zinc/day) estimated colds ~2.7–2.9 days shorter against a 7-day average, with the effect unmodified by allergy, smoking, age, sex, ethnicity, or baseline severity ^{2Reference 2Hemilä et al. · 2016Meta-analysisZinc acetate lozenges for treating the common cold: an individual patient data meta-analysis — meta-analysisView study →}.
• A survival-analysis reworking of the same patients found zinc-treated patients recovered at 3.1× the rate (95% CI 2.1–4.7); by day 5, 70% of the zinc group had recovered vs 27% on placebo (number-needed-to-treat ≈ 2.3), with no serious adverse effects reported ^{4Reference 4Hemilä et al. · 2017Meta-analysisZinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis — meta-analysisView study →}.
• A symptom-level analysis (80–92 mg/day acetate) found the biggest reductions in cough (–46%), nasal congestion (–37%), nasal discharge (–34%), scratchy throat (–33%) and hoarseness (–43%), consistent with a locally acting lozenge; there was no effect on headache or fever ^{5Reference 5Hemilä et al. · 2015Meta-analysisThe effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis — meta-analysisView study →}.

Two important honesty caveats. First, acetate is not clearly superior to a properly made gluconate lozenge: a meta-analysis restricted to >75 mg/day trials found 40% (acetate) vs 28% (gluconate), a 12-percentage-point gap that was not statistically significant (95% CI −12 to +36), and found no benefit from pushing the dose above ~100 mg/day ^{3Reference 3Hemilä et al. · 2017Meta-analysisZinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage — meta-analysisView study →}. The acetate advantage in the older literature likely reflects formulation (clean free-ion release) more than the anion itself. Second, this whole body of work is dominated by a small number of trials from overlapping author groups, the strong taste complicates blinding, and the 2024 Cochrane review — using stricter inclusion and GRADE — judged the certainty of evidence for zinc shortening colds to be low, a conclusion its authors have publicly contested ^{6,7Reference 6Nault et al. · 2024Systematic reviewZinc for prevention and treatment of the common cold — systematic review (Cochrane)View study →Reference 7Hemilä · 2024ReviewShortcomings in the Cochrane review on zinc for the common cold (2024) — commentaryView study →}. The practical read: acetate lozenges at high dose, started within ~24 h of onset, are the best-studied option and may meaningfully shorten a cold, but the effect size and even its reality remain debated.

Wilson disease — the one prescription indication

Zinc acetate (Galzin) is FDA-approved for maintenance therapy of Wilson’s disease, an inherited disorder of copper overload. Here the mechanism is the point of the drug rather than a side issue: zinc induces intestinal metallothionein, which traps dietary and endogenously secreted copper in enterocytes and carries it out in the stool, producing a negative copper balance ^{9Reference 9Brewer · 2001ReviewZinc acetate for the treatment of Wilson’s disease — reviewView study →}. Its main advantage over copper chelators is a very low toxicity profile — the chief complaint is mild gastric irritation in ~10% of patients early on ^{9Reference 9Brewer · 2001ReviewZinc acetate for the treatment of Wilson’s disease — reviewView study →}. A retrospective comparison of 59 long-treated patients found the target urinary-copper range reached in 81% on zinc acetate vs 73% on gluconate and 57% on other zinc salts, suggesting the approved acetate salt performs at least as well as alternatives, though the study was not randomised ^{10Reference 10Camarata et al. · 2019ObservationalZinc maintenance therapy for Wilson disease: a comparison between zinc acetate and alternative zinc preparations — retrospective cohortView study →}.

Note: Wilson-disease treatment is a physician-managed prescription context requiring urinary-copper monitoring. It is included here because it is the acetate salt’s formal drug indication — not as a self-supplementation use.

Dosage

Dose by elemental zinc, not salt weight (dihydrate acetate is ~30% zinc).

• Routine repletion / general supplementation: the mineral’s intake references govern here — RDA 8–11 mg/day, Tolerable Upper Intake Level 40 mg/day (adults; the UL counts supplemental plus fortified zinc, and is set largely on the copper-depletion endpoint). Typical supplemental doses of 8–30 mg elemental/day sit comfortably below the UL. See the Zinc hub for the full intake table.
• Cold lozenges (short-term only): trials used 80–92 mg elemental zinc/day, divided across several lozenges dissolved slowly in the mouth, started within ~24 hours of symptom onset and continued only for the days of the cold ^{2,4Reference 2Hemilä et al. · 2016Meta-analysisZinc acetate lozenges for treating the common cold: an individual patient data meta-analysis — meta-analysisView study →Reference 4Hemilä et al. · 2017Meta-analysisZinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis — meta-analysisView study →}. There is no evidence that pushing above ~100 mg/day improves efficacy ^{3Reference 3Hemilä et al. · 2017Meta-analysisZinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage — meta-analysisView study →}. These short-term amounts deliberately exceed the 40 mg/day UL, which is why they are for brief, acute use — not ongoing intake.

These reflect doses studied in research, not a personal recommendation.

Safety

At repletion doses zinc acetate is well tolerated. The dose-limiting issues are form- and dose-specific:

• Copper depletion is the defining chronic risk of any high zinc intake. Sustained intake at or above ~40 mg/day elemental can induce copper deficiency (anaemia, neutropenia, and — rarely, with prolonged excess — myeloneuropathy). This is the endpoint the 40 mg/day UL is built on. People taking sustained higher doses are often advised to add supplemental copper.
• Lozenge-specific effects: at the high acute doses used for colds, nausea, mouth and throat irritation, and a strong metallic taste are common and are the main reasons people stop ^{4,5Reference 4Hemilä et al. · 2017Meta-analysisZinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis — meta-analysisView study →Reference 5Hemilä et al. · 2015Meta-analysisThe effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis — meta-analysisView study →}. These are local and short-lived; no serious adverse effects were reported in the pooled cold trials ^{4Reference 4Hemilä et al. · 2017Meta-analysisZinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis — meta-analysisView study →}.
• Interactions (drug classes checked): zinc reduces the absorption of fluoroquinolone and tetracycline antibiotics and vice versa (separate by ≥2 hours); penicillamine and other copper chelators interact directly (relevant in Wilson disease); high-dose zinc can worsen copper status alongside any copper-lowering therapy. Take zinc apart from these medicines.
• Who should be cautious: anyone on the interacting drugs above; Wilson-disease patients (physician management only); and anyone already at risk of copper deficiency. General zinc cautions from the Zinc hub apply in full.

Pregnancy & lactation

Verdict: repletion doses within the RDA/UL are considered appropriate; high-dose cold lozenges are not established as safe in pregnancy and should not be used for that purpose without medical advice. Zinc is an essential nutrient with defined pregnancy RDAs, and zinc acetate has documented use in managing Wilson disease during pregnancy under specialist care ^{9Reference 9Brewer · 2001ReviewZinc acetate for the treatment of Wilson’s disease — reviewView study →}. However, the high short-term lozenge doses (80–92 mg/day) exceed the pregnancy UL and have not been evaluated for cold treatment in pregnancy. Keep supplemental zinc within the RDA/UL unless a clinician directs otherwise.

Absence of reported harm is not evidence of safety. Where a use was not studied (e.g. high-dose lozenges in pregnancy), that is stated as “not established,” not implied safe.

Related compounds / cross-links

• Hub: Zinc — full evidence base, intake references, complete safety picture.
• Sibling forms: Zinc gluconate (the other main lozenge salt), Zinc citrate, Zinc bisglycinate, Zinc picolinate, Zinc oxide (the poorly absorbed one).
• Delivers: elemental zinc. Counter-nutrient: copper (depleted by sustained high zinc intake).

References